Apellis Pharmaceuticals, Inc.
APLS
$24.26
$1.315.71%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 374.78M | 362.34M | 416.14M | 403.69M | 368.04M |
Total Receivables | 229.23M | 244.38M | 271.72M | 283.97M | 308.85M |
Inventory | 121.24M | 93.83M | 82.48M | 129.31M | 162.18M |
Prepaid Expenses | 13.47M | 16.14M | 9.51M | 8.98M | 11.77M |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 16.90M | 11.04M | 9.10M | 7.96M | 9.13M |
Total Current Assets | 755.61M | 727.72M | 788.95M | 833.90M | 859.97M |
|
|||||
Total Current Assets | 755.61M | 727.72M | 788.95M | 833.90M | 859.97M |
Net Property, Plant & Equipment | 16.75M | 17.77M | 19.04M | 20.44M | 20.16M |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 49.03M | 61.80M | 77.06M | 47.53M | 24.35M |
Total Assets | 821.39M | 807.29M | 885.05M | 901.87M | 904.48M |
|
|||||
Total Accounts Payable | 54.24M | 55.29M | 38.57M | 42.73M | 38.27M |
Total Accrued Expenses | 139.00M | 116.15M | 140.18M | 139.84M | 122.78M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 7.42M | 6.94M | 6.75M | 6.79M | 6.21M |
Total Finance Division Other Current Liabilities | -- | -- | -- | 1.90M | 1.90M |
Total Other Current Liabilities | -- | -- | -- | 1.90M | 1.90M |
Total Current Liabilities | 200.66M | 178.38M | 185.51M | 191.26M | 169.17M |
|
|||||
Total Current Liabilities | 200.66M | 178.38M | 185.51M | 191.26M | 169.17M |
Long-Term Debt | 454.04M | 453.42M | 452.83M | 452.25M | 457.21M |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | 8.31M | 9.19M | 10.20M | 11.41M | 11.09M |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | 2.08M | 2.08M | 7.97M | 9.83M | 2.69M |
Total Liabilities | 665.09M | 643.07M | 656.51M | 664.75M | 640.16M |
|
|||||
Common Stock & APIC | 3.33B | 3.29B | 3.27B | 3.24B | 3.21B |
Retained Earnings | -3.17B | -3.13B | -3.04B | -3.00B | -2.94B |
Treasury Stock & Other | -2.57M | -3.05M | -3.31M | -3.14M | -3.36M |
Total Common Equity | 156.31M | 164.22M | 228.54M | 237.12M | 264.33M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 156.31M | 164.22M | 228.54M | 237.12M | 264.33M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 156.31M | 164.22M | 228.54M | 237.12M | 264.33M |
|